

SUPPLEMENTARY TABLE**Table S1: Cost savings achieved at different levels of guideline adherence**

Assumed adherence to guideline recommendations (%)*	NICE			GOLD		
	Total overall annual costs (GBP)	Cost saving lost £ (GBP) (%) vs 100% adherence	Total cost savings (%)	Total overall annual costs (GBP)	Total cost savings (%)	Cost saving lost £ (GBP) (%) vs 100% adherence
0	£571,684,984	£46.9 million (9%)	0	£571,684,984	0	£43.7 million (8%)
25	£559,965,738	£35.2 million (7%)	2	£560,759,767	2	£32.8 million (6%)
50	£548,245,899	£23.4 million (4%)	4	£549,833,953	4	£21.8 million (4%)
75	£536,537,297	£11.7 million (2%)	6	£538,909,380	6	£10.9 million (2%)
100	£524,808,051	Total guideline adherence: £0 million (0%)	8	£527,984,163	8	Total guideline adherence: £0 million (0%)

*Assuming only a proportion of the number of patients is treated according to guidelines recommendations. This percentage was applied across the entire population. Including equal proportions in each patients groups.

GBP, pound sterling; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NICE, National Institute for Health and Care Excellence.